Epoetin alfa (Procrit)

General information

Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.
Route: SC, IV
Extravasation: no information

• ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Patient drug information

• Epoetin alfa (Procrit) patient instructions for use
• Brief patient counseling information can be found on pages 25-26 of the Epoetin alfa (Procrit) package insert
• Epoetin alfa (Procrit) patient drug information (Chemocare)
• Epoetin alfa (Procrit) patient drug information (UpToDate)

History of changes in FDA indication

• 6/1/1989: Initial FDA approval

Also known as

Synonyms
Ceriton	Dynepo	Epoch	Epoetin	Epoetin Alfa	Epoetin Beta	Epoetin Delta	Epoetin Zeta
Epofer	Epogen	Epogin	Epoimmun	Epomax	Epopen	Epox	Epoyet
Eprex	Eritrelan	Erypo	Erypo FS	Erythropoetin	Erythropoietin	Erythropoietin Human	Erythrostim
Espo	Espo Kirin	Espo Sankyo	Globuren	Hemapo	Hemax	KE Long YI BAO	LG Espogen
Procrit	Recormon	Recormon N	Recormon NEU	Recormon PS	Recormon S	Recormon SE	Vepox
Vintor	Wepox